Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Massive french study to track virus effects on pregnant women and kids for 7 years

NCT ID NCT07412977

Knowledge-focused Sponsor: ANRS, Emerging Infectious Diseases Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will follow 5,160 pregnant women in France who have HIV, hepatitis B, hepatitis C, or an arbovirus infection (like Zika or dengue), along with their children, for up to 7 years. Researchers want to learn how these viruses and their treatments affect pregnancy, the mother's health, and the child's development. The goal is to gather information to improve care, not to test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 5,160 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Feb 2026

An estimate. Start dates often move.

Expected to finish

Dec 2039

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Pregnant women living with either HIV and/or HBV and/or HCV and/or Arbovirus will be enrolled in the study. After delivery, their child/children will also be enrolled.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Pregnant women : * Cis-gender pregnant woman wishing to carry her pregnancy to term and give birth in one of the maternity units participating in the research, whatever the term of pregnancy (inclusion as soon as possible after conception, whatever the outcome); * Age ≥18 years; * Viral infection studied known before pregnancy or diagnosed during pregnancy; * Signed, free, informed and written consent; * Be cared for in one of the maternity units taking part in the study Newborns/children: \- Free, informed, written and signed consent of parental guardians. Exclusion Criteria: Pregnant women : * Planned delivery in a non-study center; * Planned absence that could hinder participation in the research; * Vulnerable population (minors, persons under guardianship or trusteeship, or persons deprived of their liberty by judicial or administrative decision); * Level of French oral comprehension insufficient according to the investigator for the research process understanding Newborns/children: * Refusal of parental authority to allow newborn/child to participate in study * Follow-up of the child planned in a center not participating in the study * Scheduled absence of parents that could hinder the child's participation in the study;

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Arbovirus infections are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

arbovirus infection cognitive disorder hepatitis hepatitis B virus infection hepatitis C virus infection hepatitis D virus infection HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Arbovirus infections HBV infection HCV infection HDV infection HIV infection

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centre de Méthodologie et de Gestion de Bichat

    Paris, 75018, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.